Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.48)
# 942
Out of 5,124 analysts
226
Total ratings
46.01%
Success rate
21.45%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $6.90 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $26.71 | +4.83% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $170.00 | -11.76% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $182.64 | -16.23% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $12.70 | +10.24% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $78.41 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $11.29 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $31.74 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $37.42 | +55.00% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $27.98 | +53.68% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $63.54 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.55 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $141.83 | +9.29% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.15 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $16.51 | +111.99% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $8.82 | +47.39% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.18 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.39 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.09 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.34 | +45.67% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $46.55 | +7.41% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.64 | -11.35% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.35 | +1,059.08% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.09 | +266.97% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $44.82 | +29.41% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.16 | +94,727.59% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.87 | +1,262.86% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $0.95 | +214.53% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $3.56 | +208.99% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $7.70 | +55.84% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.72 | +2,400.00% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.85 | +601.75% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $39.99 | +400.13% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.63 | +145.40% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.98 | +1,112.12% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.74 | +8,175.86% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.32 | +203.03% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $67.30 | -42.05% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $34.80 | -56.90% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.42 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.61 | +4,886.15% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.90
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $26.71
Upside: +4.83%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $170.00
Upside: -11.76%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $182.64
Upside: -16.23%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $12.70
Upside: +10.24%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $78.41
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.29
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.74
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $37.42
Upside: +55.00%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $27.98
Upside: +53.68%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $63.54
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.55
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $141.83
Upside: +9.29%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $16.51
Upside: +111.99%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $8.82
Upside: +47.39%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.18
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.39
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.09
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.34
Upside: +45.67%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $46.55
Upside: +7.41%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.64
Upside: -11.35%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.35
Upside: +1,059.08%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.09
Upside: +266.97%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $44.82
Upside: +29.41%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.16
Upside: +94,727.59%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.87
Upside: +1,262.86%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $0.95
Upside: +214.53%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $3.56
Upside: +208.99%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.70
Upside: +55.84%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.72
Upside: +2,400.00%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.85
Upside: +601.75%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $39.99
Upside: +400.13%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.63
Upside: +145.40%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.98
Upside: +1,112.12%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.74
Upside: +8,175.86%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.32
Upside: +203.03%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $67.30
Upside: -42.05%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $34.80
Upside: -56.90%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.42
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.61
Upside: +4,886.15%